Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOCRTEC2101: Sintilimab + Preoperative Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05357846Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2022
- Primary completion
- Jan 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Nov 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05357846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357846.